Gehe First-Half Profits Helped By AAH Acquisition

20 August 1995

German drug wholesaler Gehe AG reported a 34% improvement in first-half 1995 pretax profits, which reached 151 million Deutschemarks ($105.2 million).

The company said that group sales for the period were "considerably influenced" by the acquisition in April of UK drug wholesaler AAH Holdings (which it acquired through a hostile bid; Marketletters passim), without which turnover would have increased only 8.5%. For the year as a whole, Gehe expects total turnover to reach 18.5 billion marks ($12.89 billion), which would be an increase of around 22% on the 1994 level of 15.2 billion marks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight